Cannabis Industry News: DEA Registration, Curaleaf’s Aurora Bid and MSO Capital Moves

Federal medical-cannabis implementation advanced this week as DEA opened its standard registration pathway to manufacturers, distributors and laboratories. Curaleaf formally increased its hostile bid for Aurora, while Vireo borrowed against cultivation real estate and Trulieve used cash to retire cultivation-related debt. Together, the developments show where capital is moving: regulated medical infrastructure, international distribution and ownership of productive assets.

1. DEA opens Form 225 registration to medical-cannabis operators

On October 5, DEA added medical-marijuana manufacturers, distributors and analytical laboratories to its Form 225 registration process. Dispensaries have a separate Form 224M pathway. DEA’s registration page now lists both routes. dea.gov

This is implementation of the federal rule that already placed marijuana covered by qualifying state medical licenses in Schedule III. It is not a new rescheduling proposal. The broader proceeding concerning marijuana outside the protected medical framework remains separate.

For cultivators and processors, registration is the practical gateway to federal recognition under the medical framework. Applicants should expect scrutiny of state licensure, ownership, operating addresses, controlled-substance handling and background information. Application availability does not equal approval, and businesses applying now are outside the early-application window tied to DEA’s six-month processing target.

Sources: DEA rescheduling and registration page · DEA registration portal and forms · Registration-pathway reporting

2. Curaleaf formally raises and extends its hostile offer for Aurora

Curaleaf filed its revised offer on October 6 after announcing the increase one day earlier. Aurora shareholders are being offered US$1 in cash plus 0.4013 Curaleaf subordinate voting shares per Aurora share. Curaleaf calculated an implied value of US$5 per share using its October 2 closing price, 25% above the initial offer’s stated value. Because most consideration is stock, the value received will move with Curaleaf’s share price, subject to the offer’s US$6 cap. sec.gov

Curaleaf says the combined businesses would have more than US$1.5 billion in trailing revenue, nearly US$350 million in adjusted EBITDA and at least US$40 million in annual cost synergies. Those are bidder calculations based partly on public information, not realized results. Curaleaf has not completed due diligence with Aurora. sec.gov

Aurora’s board has not endorsed the revised bid. Its special committee is reviewing the formal filing and has advised shareholders to take no action pending a recommendation. The offer expires December 4 unless changed, withdrawn or extended. sec.gov

The strategic assets at issue extend beyond Canadian production. Aurora brings EU-GMP cultivation and manufacturing, established European medical revenue and operations serving Australia and New Zealand. Curaleaf already operates an international supply and distribution network. The transaction would therefore combine overlapping medical-cannabis infrastructure across several countries, but the future footprint and any facility consolidation remain unknown.

Sources: Curaleaf’s SEC-filed offer announcement · Aurora’s response

3. Vireo borrows $60 million against New York and Florida production assets

Vireo announced October 5 that property subsidiaries entered an eight-year, US$60 million real-estate loan bearing 8.5% interest and maturing April 2, 2034. Approximately US$49 million refinances senior debt associated with the Johnstown, New York, cultivation and production facility. The remaining US$11 million finances the acquisition of Vireo’s Palatka, Florida, facility, which had been leased from an outside owner. globenewswire.com

The properties secure the loan through first-priority mortgages and related collateral. At the stated rate, US$60 million represents approximately US$5.1 million of annual interest before amortization and fees. Vireo is exchanging leased or option-controlled real estate for owned infrastructure while extending the associated financing into 2034.

That structure provides longer-term control of two production sites, but the announcement does not disclose facility-level production, utilization, cost per gram or cash returns. Those numbers will determine whether ownership creates more value than the capital committed.

Source: Vireo financing announcement

4. Trulieve repays the $65 million mortgage on a Florida cultivation property

Trulieve announced October 7 that it repaid approximately US$65 million secured by its Jefferson County, Florida, cultivation site, reducing reported outstanding debt to approximately US$225 million. The company did not disclose its post-payment cash balance, a prepayment charge or any swap-termination cost. Oct 7, 2026

Its June filing identified the relevant mortgage as carrying a fixed 7.53% rate through an interest-rate swap and maturing January 1, 2028. Based on the June balance, eliminating the debt removes roughly US$4.9 million of annual interest before any repayment costs. That is a calculation from disclosed terms, not company guidance. investors.trulieve.com

Vireo and Trulieve made opposite capital moves for different purposes: Vireo added secured debt to own production assets, while Trulieve spent cash to remove debt from an existing cultivation property. The comparison cannot establish which decision is superior without current liquidity, asset returns and alternative uses of capital.

Sources: Trulieve repayment announcement · Debt terms in Trulieve’s filing

5. Cannara increases its Curaleaf export contract from C$21 million to C$34 million

Cannara expanded its two-year international supply agreement with Curaleaf on October 5. The stated potential contract value increased from C$21 million to C$34 million if the committed volumes and other agreement terms are fully realized. Cannara now has 15 of 24 cultivation rooms operating at its Valleyfield facility. Cannara Biotech

Cannara has not yet obtained EU-GMP certification for Valleyfield’s processing center. Until it does, flower will be dried and processed at Curaleaf’s EU-GMP-certified Canadian facility before release to international medical markets.

This is a useful model for exporting cultivation output before building a complete certified processing route internally: grow through a contracted volume relationship, then use a certified downstream partner. The disclosed contract ceiling should not be treated as guaranteed revenue, and neither party disclosed price per kilogram or destination-market volumes.

Source: Cannara’s expanded supply agreement

6. Spherex agrees to acquire indoor and outdoor Colorado cultivation

Colorado manufacturer Spherex announced October 6 that it agreed to acquire a Denver-area indoor cultivation facility and an outdoor operation near Trinidad from The Cannabist Company and its affiliates. Approximately 60 cultivation employees are expected to join Spherex, increasing its workforce from roughly 40 to nearly 100. The price, canopy and production volume were not disclosed, and the transaction has not yet been reported as completed. markets.financialcontent.com

Spherex said outside supply constraints had produced manufacturing backups and delayed orders. The acquisition is therefore tied to a documented production bottleneck, although the company says it will continue sourcing from independent growers.

This is vertical integration undertaken to improve supply control, not proof that internal cultivation will be cheaper. The unanswered questions are facility utilization, flower quality, outdoor extraction recovery, fixed costs and whether the acquired output matches Spherex’s product mix.

Source: Transaction announcement

Other developments

A federal judge modified an Ohio preliminary injunction on October 5 to prevent enforcement of an in-state cultivation or processing requirement against Fresh Farms’ participation in the Ohio market. The ruling is preliminary and concerns Fresh Farms and products protected by the existing injunction; it is not a final invalidation of every Ohio hemp restriction. Court docket and order. GovInfo

New licenses and market openings

Minnesota reported 396 cannabis licenses issued as of October 5, up from 386 on September 28. The increase consisted of eight additional microbusiness licenses and two retailer licenses. The state now reports 288 licensed microbusinesses, 24 cultivators, 25 mezzobusinesses and 20 retailers. These are license issuances, not confirmation that ten additional businesses opened or began producing. Minnesota OCM data. mn.gov

Henrico County, Virginia, will consider local cannabis zoning amendments on October 15. The draft requires cultivation, processing, testing and transportation facilities to remain 1,000 feet from residential districts. Outdoor cultivation would require opaque six-foot screening and a 25-foot lot-line setback. Retail stores and microbusinesses would face separate 1,000-foot sensitive-use buffers. These provisions remain proposed. Henrico draft ordinance. henrico.gov

What to watch next

• October 13: Responses are due in the separate proceeding addressing broader federal marijuana rescheduling.

• October 15: Henrico’s Planning Commission hears the proposed Virginia cannabis zoning amendments.

• Aurora’s board response: Watch its formal recommendation on Curaleaf’s revised bid and any disclosed alternatives.

• November 5: Trulieve reports third-quarter results. The September 30 balance sheet predates the October debt repayment, so current liquidity will require management clarification.

• DEA registrations: Watch for the first approved manufacturer, distributor and laboratory registrations, rather than counting submitted applications as federally registered operations.